Video: Sitting Down With… John Tomtishen
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
Clinical Scorecard: Video: Sitting Down With… John Tomtishen
At a Glance
| Category | Detail |
|---|
| Condition | Cell therapy development |
| Key Mechanisms | The interview discusses product characterization, chemistry, manufacturing and controls (CMC), scalability, and manufacturing strategies. |
| Target Population | Cell therapy developers |
| Care Setting | Cell therapy development and manufacturing |
Key Highlights
- John Tomtishen discusses changes he has witnessed across the cell therapy field.
- He explains why developers should prioritize product characterization and CMC early in development.
- The interview explores technologies and manufacturing strategies that could improve scalability.
- Tomtishen shares his perspective on bringing the next generation of cell therapies to more patients.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
The interview concerns cell therapy development; no specific patient population or prescribing data are provided.
The interview addresses development and manufacturing strategies for cell therapies, not specific treatment regimens.
Clinical Best Practices
Related Resources & Content
